Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Income: 2014-2025

Historic Net Income for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to -$42.3 million.

  • KalVista Pharmaceuticals' Net Income rose 5.34% to -$42.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$156.4 million, marking a year-over-year decrease of 65.27%. This contributed to the annual value of -$183.5 million for FY2025, which is 44.86% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Net Income is -$42.3 million, which was down 4.51% from -$40.4 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Net Income registered a high of -$29.0 million during Q1 2024, and its lowest value of -$44.6 million during Q2 2024.
  • For the 2-year period, KalVista Pharmaceuticals' Net Income averaged around -$39.1 million, with its median value being -$41.4 million (2024).
  • Data for KalVista Pharmaceuticals' Net Income shows a peak YoY rose of 5.34% (in 2025) over the last 5 years.
  • Over the past 2 years, KalVista Pharmaceuticals' Net Income (Quarterly) stood at -$40.4 million in 2024, then increased by 5.34% to -$42.3 million in 2025.
  • Its Net Income was -$42.3 million in Q2 2025, compared to -$40.4 million in Q3 2024 and -$44.6 million in Q2 2024.